Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
INVENTIVA Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 2024, compared to €26.9 million, €0.01 million and €9.0 million as of December 31, 2023, respectively. The fourth scheduled DMC meeting recommended to continue the NATiV3 Phase III clinical trial without modification of